146 related articles for article (PubMed ID: 36259705)
1. [Janus kinase inhibitors : new perspectives for precision medicine ?].
Tachet J; Dumusc A; Conrad C; Grandoni F; Chalandon Y; Ribi C; Buclin T; Girardin F
Rev Med Suisse; 2022 Oct; 18(800):1979-1983. PubMed ID: 36259705
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a multiplex HPLC-MS/MS assay for the monitoring of JAK inhibitors in patient plasma.
Tachet J; Versace F; Mercier T; Buclin T; Decosterd LA; Choong E; Girardin FR
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Nov; 1230():123917. PubMed ID: 37956468
[TBL] [Abstract][Full Text] [Related]
3. State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis.
El Jammal T; Sève P; Gerfaud-Valentin M; Jamilloux Y
Expert Opin Pharmacother; 2021 Feb; 22(2):205-218. PubMed ID: 32967471
[TBL] [Abstract][Full Text] [Related]
4. JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future.
Angelini J; Talotta R; Roncato R; Fornasier G; Barbiero G; Dal Cin L; Brancati S; Scaglione F
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32635659
[TBL] [Abstract][Full Text] [Related]
5. JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells.
Fujita Y; Matsuoka N; Temmoku J; Furuya-Yashiro M; Asano T; Sato S; Matsumoto H; Watanabe H; Kozuru H; Yatsuhashi H; Kawakami A; Migita K
BMC Immunol; 2020 Jun; 21(1):35. PubMed ID: 32539713
[TBL] [Abstract][Full Text] [Related]
6. [Role of janus kinase inhibitors in the treatment of rheumatic diseases].
Krüger K
Internist (Berl); 2019 Nov; 60(11):1215-1220. PubMed ID: 31486859
[TBL] [Abstract][Full Text] [Related]
7. [Janus kinase inhibitors : State of the art in clinical use and future perspectives].
Alten R; Mischkewitz M; Stefanski AL; Dörner T
Z Rheumatol; 2020 Apr; 79(3):241-254. PubMed ID: 32219519
[TBL] [Abstract][Full Text] [Related]
8. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
Roskoski R
Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of Janus Kinase inhibitor selectivity.
Choy EH
Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Wang F; Sun L; Wang S; Davis JM; Matteson EL; Murad MH; Luo F; Vassallo R
Mayo Clin Proc; 2020 Jul; 95(7):1404-1419. PubMed ID: 32499126
[TBL] [Abstract][Full Text] [Related]
11. Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.
Veeravalli V; Dash RP; Thomas JA; Babu RJ; Madgula LMV; Srinivas NR
Drug Saf; 2020 Aug; 43(8):711-725. PubMed ID: 32367507
[TBL] [Abstract][Full Text] [Related]
12. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
McInnes IB; Byers NL; Higgs RE; Lee J; Macias WL; Na S; Ortmann RA; Rocha G; Rooney TP; Wehrman T; Zhang X; Zuckerman SH; Taylor PC
Arthritis Res Ther; 2019 Aug; 21(1):183. PubMed ID: 31375130
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
[TBL] [Abstract][Full Text] [Related]
14. Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis.
Venetsanopoulou AI; Voulgari PV; Drosos AA
Expert Rev Clin Immunol; 2022 May; 18(5):485-493. PubMed ID: 35535405
[TBL] [Abstract][Full Text] [Related]
15. In brief: New warnings for janus kinase inhibitors.
Med Lett Drugs Ther; 2021 Oct; 63(1634):160. PubMed ID: 34550959
[No Abstract] [Full Text] [Related]
16. Janus kinase inhibitors alter NK cell phenotypes and inhibit their antitumour capacity.
Meudec L; Richebé P; Pascaud J; Mariette X; Nocturne G
Rheumatology (Oxford); 2023 Aug; 62(8):2855-2863. PubMed ID: 36583542
[TBL] [Abstract][Full Text] [Related]
17. Upadacitinib (Rinvoq) - a new JAK inhibitor for rheumatoid arthritis.
Med Lett Drugs Ther; 2019 Nov; 61(1585):183-185. PubMed ID: 31770358
[No Abstract] [Full Text] [Related]
18. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
Jegatheeswaran J; Turk M; Pope JE
Immunotherapy; 2019 Jun; 11(8):737-754. PubMed ID: 30955397
[TBL] [Abstract][Full Text] [Related]
19. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.
Fitton J; Melville AR; Emery P; Nam JL; Buch MH
Rheumatology (Oxford); 2021 Sep; 60(9):4048-4054. PubMed ID: 33331938
[TBL] [Abstract][Full Text] [Related]
20. [JAK inhibitors: Perspectives in internal medicine].
El Jammal T; Gerfaud-Valentin M; Sève P; Jamilloux Y
Rev Med Interne; 2019 Dec; 40(12):816-825. PubMed ID: 31699450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]